Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

Abstract Background Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become standard of care for patients with advanced non-small cell lung cancer and increasing numbers of other cancer types. In this report, we discuss the clinical history, pathological evaluation, an...

Full description

Bibliographic Details
Main Authors: Hong Li, Weijie Ma, Ken Y. Yoneda, Elizabeth H. Moore, Yanhong Zhang, Lee L. Q. Pu, Garrett M. Frampton, Michael Molmen, Philip J. Stephens, Tianhong Li
Format: Article
Language:English
Published: BMC 2017-02-01
Series:Journal of Hematology & Oncology
Subjects:
PD-1 inhibitor
Nivolumab
Cancer immunotherapy
Immune-related adverse event
Pneumonitis
Complete remission
Online Access:http://link.springer.com/article/10.1186/s13045-017-0433-z

Internet

http://link.springer.com/article/10.1186/s13045-017-0433-z

Similar Items